Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Victoza, Saxenda
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a type of incretin mimetic, used for the treatment of type 2 diabetes and chronic weight management. It works by mimicking the effects of GLP-1, a naturally occurring hormone that stimulates insulin release, suppresses glucagon secretion, slows gastric emptying, and reduces appetite. Liraglutide is administered subcutaneously once daily.
For improving glycemic control in adults with type 2 diabetes and for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.
Liraglutide has been associated with an increased risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in rodents. It is unknown whether liraglutide causes MTC in humans.
Outcome:
Increased risk of bleeding
Mechanism:
Possible alteration of INR
Outcome:
Increased risk of hypoglycemia
Mechanism:
Additive hypoglycemic effects
Outcome:
Slight alteration in digoxin absorption
Mechanism:
Delayed gastric emptying
Most likely new formulation: oral liraglutide (2024, 85% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood of continued approval for both diabetes and obesity indications.
Antidiabetic Agent, GLP-1 Receptor Agonist, Weight Loss Agent
Glucagon-like peptide-1 analog